NovoCure Ltd (NVCR) stock
NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$11.14−0.16 (-1.42%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
NovoCure price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
NovoCure's price to sales ratio was 2.0× on Nov 11, 2026, against 2.2× a year earlier. Over the last 5 years it ranged from 1.9× to 17.6×, with a median of 3.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.0× | −0.3 |
| 2025 | Dec 31, 2025 | 2.3× | −3.3 |
| 2024 | Dec 31, 2024 | 5.6× | +2.4 |
| 2023 | Dec 29, 2023 | 3.2× | −11.0 |
| 2022 | Dec 30, 2022 | 14.2× | −0.1 |
| 2021 | Dec 31, 2021 | 14.3× | −24.9 |
| 2020 | Dec 31, 2020 | 39.1× | +13.2 |
| 2019 | Dec 31, 2019 | 25.9× | +12.5 |
| 2018 | Dec 31, 2018 | 13.4× | +1.7 |
| 2017 | Dec 29, 2017 | 11.8× | +1.4 |
| 2016 | Dec 30, 2016 | 10.4× | −1.0 |
| 2015 | Dec 31, 2015 | 11.3× | – |
See a number that looks wrong?